---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-273532"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:31:55.046363+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Atea Pharma Q3 net loss widens to $33.1M; cash at $595.1M; pipeline milestones on track

## Summary
- Net loss of $33.1M ($0.40/share) vs $8.1M ($0.10) a year ago, driven by R&D spending surge to $28.2M.
- Cash, cash equivalents and marketable securities $595.1M at Sept 30, down $13M from June 30.
- Phase 3 SUNRISE-3 for bemnifosbuvir in COVID-19 enrollment ongoing; first interim analysis expected Q1 2024.
- Phase 2 HCV combination trial (bemnifosbuvir + ruzasvir) lead-in cohort fully enrolled; initial data also due Q1 2024.
- Interest income rose to $7.9M from $4.4M on higher yields; total operating expenses $40.8M.

## SEC filing metadata
- accession: 0001193125-23-273532
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/0001193125-23-273532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/d524760d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-273532
- JSON: https://secwatch.observer/filing/0001193125-23-273532.json
- Plain text: https://secwatch.observer/filing/0001193125-23-273532.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/0001193125-23-273532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.